论文部分内容阅读
西班牙共约250个生物技术组织,1988年80个以上申请了欧共体修改后的生物技术行动计划(BAP)的资助,但只有一家公司属于此列。直至80年代中期,生物技术仍未受到重视,仅集中于几家国际性大公司的子公司。虽然有几所大学的附属机构开始用腹水生产单克隆抗体,但没有一家公司能够独立进行基因操作。现约有50家公司积极从事生物技术工作。但只有15至20家被认为与美国的这类公司一样。西班牙生物技术研究主要集中于马德里和巴塞罗那。
Spain has a total of about 250 biotech organizations, and in 1988, more than 80 applied for funding from the revised biotechnological action plan (BAP) of the European Community, but only one company is included. Until the mid-1980s, biotechnology was still not valued, focusing only on subsidiaries of several large international companies. Although there are several university affiliates that begin producing monoclonal antibodies in ascites, no single company can independently perform genetic manipulation. About 50 companies are active in biotechnology. But only 15 to 20 are considered the same as those in the United States. Spanish biotechnology research focuses mainly on Madrid and Barcelona.